$ISRG

Ladd Amy L sold $180K of ISRG

Ladd Amy L sold 472 shares of INTUITIVE SURGICAL INC (ISRG) at an average of $381.15 ($379.00–$393.10, $0.18M total) across 2 trades over 2026-08-10 to 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ladd Amy L
Published Aug 11, 2026, 9:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 10:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ISRG
Neutral
high confidence
Mentioned
$ISRG
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ISRGNeutralLow
01

Why it matters

The only new information is the disclosed sale size, timing, and that it was executed under a pre-arranged 10b5-1 plan; there is no guidance, litigation, product, or financial update.

02

Market read

Routine 10b5-1 insider selling is typically low-signal for price, so it is unlikely to drive a durable repricing without additional company catalysts.

03

What to watch

The filing does not state reasons for sale, and the post-transaction holdings remain small (179 shares), reducing interpretability versus larger insider positions.

Relevance 3/10Novelty 2/10Timing: filed 2026-08-11, covering sales on 2026-08-10 to 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for Intuitive Surgical (ISRG) by director Ladd Amy L.

Company-level read

Ticker impact

$ISRGNeutralHigh confidence
Context

Form 4 shows director Ladd Amy L sold about $179.9K of ISRG shares in two open-market trades under a 10b5-1 plan.

Expected impact

Likely minimal immediate impact; any reaction would be more sentiment-driven than fundamental.

Evidence & confidence

The filing is an SEC Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific operational or financial information.

Market effects

No sector-level implications; this is company-specific insider trading with no stated business change.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with private concerns, so traders may watch for follow-on sales or other negative disclosures.

Key entities

  • ISRG

    Intuitive Surgical, the company whose shares were sold by a director.

  • Ladd Amy L

    Director who executed two open-market sales totaling $179,903.20 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ISRGMedAI 8/10

Intuitive Surgical Vs. Stryker: Wall Street Loves Both But One Has a Quiet Advantage That Will Make Investors Money

Intuitive Surgical (ISRG) and Stryker (SYK) both reported strong Q2 2026 earnings, with ISRG highlighting 85% recurring revenue and SYK showing 9.4% revenue growth. ISRG's da Vinci systems and SYK's MedSurg and Neurotechnology segments drove performance. ISRG's CEO noted portfolio strength, while SYK's CEO cited regained momentum. Analysts favor ISRG for its compounding moat and recurring revenue model, with 25 EPS revisions in 30 days.

$ISRGMedAI 8/10

New da Vinci Surgical Robot Secures Marketing Approval: Entering Olympus’ Core Dominant Surgical Market

Intuitive Surgical received FDA approval for its flexible gastrointestinal robot, IG1000, marking its entry into a market dominated by Olympus. The company plans to refine the product before commercial launch, focusing on clinical benefits and user experience. Analysts note the product's force feedback and suturing capabilities, highlighting Intuitive's strategic expansion beyond its da Vinci surgical robots.

$NKELow

Can These Beaten Down Stocks Bounce Back?

NIKE (NKE) and Intuitive Surgical (ISRG) shares have underperformed in 2026. NIKE reported Q4 adjusted EPS of $0.20, beating estimates, but revenue declined 1%. ISRG's Q2 adjusted EPS rose 27.9%, topping estimates, with revenue up 18.5%. Both face challenges, with NIKE struggling with sales declines and ISRG dealing with valuation concerns and slower procedure growth.

$ABTMed

Abbott vs. Intuitive Surgical: Which MedTech Stock Offers Better Long-Term Upside?

Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) reported strong quarterly results, with Abbott raising its annual profit outlook and Intuitive beating revenue and earnings expectations. Abbott's diversification across diagnostics, medical devices, and nutrition drove growth, while Intuitive's robotic surgery ecosystem and recurring revenue model supported its performance. Despite the positive results, Intuitive's shares declined due to slowing domestic procedure growth. Abbot

$DHRMedAI 8/10

Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?

Danaher (DHR) and Intuitive Surgical (ISRG) present contrasting growth paths. Danaher benefits from improving life sciences spending, with strong bioprocessing orders and $100M revenue shifted to next year. Intuitive Surgical reports 18% YoY growth in da Vinci system placements, 70% non-GAAP gross margin, and 85% recurring revenue. Investors must decide between cyclical recovery and structural growth.